Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.

Wu Y, Qu X, Wang Y, Xia J, Gu Y, Qian Q, Hong Y.

Andrologia. 2018 Nov 16:e13198. doi: 10.1111/and.13198. [Epub ahead of print] Review.

PMID:
30443968
2.

A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.

Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.

Eur Urol. 2015 Nov;68(5):750-3. doi: 10.1016/j.eururo.2015.02.002. Epub 2015 Feb 17.

PMID:
25700565
3.

Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

Eur Urol. 2016 Nov;70(5):824-828. doi: 10.1016/j.eururo.2015.12.013. Epub 2015 Dec 29.

4.

Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.

Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):151-62. doi: 10.1038/pcan.2015.58. Epub 2016 Jan 19. Review. Erratum in: Prostate Cancer Prostatic Dis. 2016 Jun;19(2):222. Kaur, H [added].

PMID:
26782711
5.

Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.

Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y.

Medicine (Baltimore). 2018 Jan;97(3):e9601. doi: 10.1097/MD.0000000000009601. Review.

6.

Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.

He Q, Liao BH, Xiao KW, Zhou L, Feng SJ, Li H, Wang KJ.

Int Urol Nephrol. 2018 Dec;50(12):2113-2121. doi: 10.1007/s11255-018-1982-y. Epub 2018 Sep 19. Review.

PMID:
30232722
7.

The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.

Liu B, Zhu L, Zhong J, Zeng G, Deng T.

Sex Med. 2018 Sep;6(3):185-192. doi: 10.1016/j.esxm.2018.03.001. Epub 2018 Jun 5. Review.

8.

Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.

Deng T, Duan X, Liu B, Lan Y, Cai C, Zhang T, Zhu W, Mai Z, Wu W, Zeng G.

Neoplasma. 2018;65(2):216-221. doi: 10.4149/neo_2018_170111N23.

PMID:
29534582
9.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F.

Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22. Review.

PMID:
26806655
10.

Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.

Aoun F, Slaoui A, Walid AHO, Albisinni S, Assenmacher G, de Plaen E, Azzo JM, Peltier A, Roumeguère T.

Prog Urol. 2018 Oct;28(12):560-566. doi: 10.1016/j.purol.2018.07.004. Epub 2018 Sep 7.

PMID:
30201551
11.

Perineural invasion is an independent predictor of biochemical recurrence of prostate cancer after local treatment: a meta-analysis.

Meng Y, Liao YB, Xu P, Wei WR, Wang J.

Int J Clin Exp Med. 2015 Aug 15;8(8):13267-74. eCollection 2015.

12.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

13.

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N.

Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30752-8. doi: 10.1016/j.eururo.2018.10.011. [Epub ahead of print] Review.

PMID:
30342843
14.

Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.

Fode M, Østergren PB, Jensen CFS, Jakobsen H, Sønksen J.

Scand J Urol. 2018 Apr;52(2):108-110. doi: 10.1080/21681805.2017.1387603. Epub 2017 Oct 23.

PMID:
29057723
15.

Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.

Megas G, Papadopoulos G, Stathouros G, Moschonas D, Gkialas I, Ntoumas K.

BJU Int. 2013 Jul;112(2):E169-76. doi: 10.1111/j.1464-410X.2012.11561.x. Epub 2012 Dec 18.

16.

Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis.

Bai PD, Hu MB, Xu H, Zhu WH, Hu JM, Yang T, Jiang HW, Ding Q.

World J Surg Oncol. 2015 Nov 5;13:311. doi: 10.1186/s12957-015-0725-0.

17.

Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients.

Hu MB, Xu H, Bai PD, Jiang HW, Ding Q.

Med Oncol. 2014 Feb;31(2):829. doi: 10.1007/s12032-013-0829-8. Epub 2014 Jan 5.

PMID:
24390417
18.

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L.

Eur Urol. 2016 Nov;70(5):808-815. doi: 10.1016/j.eururo.2016.04.035. Epub 2016 May 10.

PMID:
27178449
19.

Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.

Kim SJ, Kim JH, Chang HK, Kim KH.

J Exerc Rehabil. 2016 Jun 30;12(3):143-7. doi: 10.12965/jer.1632646.323. eCollection 2016 Jun. Review.

20.

Does night-shift work increase the risk of prostate cancer? a systematic review and meta-analysis.

Rao D, Yu H, Bai Y, Zheng X, Xie L.

Onco Targets Ther. 2015 Oct 5;8:2817-26. doi: 10.2147/OTT.S89769. eCollection 2015.

Supplemental Content

Support Center